AstraZeneca heads for Roche battle with Imfinzi small-cell survival win

Right now, Rocheís Tecentriq is the only immuno-oncology therapy approved in small cell lung cancer. But it may soon have to make some room for AstraZenecaís Imfinzi. Adding Imfinzi to standard-of-care chemo reduced newly diagnosed extensive-stage patientsí risk of death by 27% in a phase 3 study, the drugmaker said Monday at the World Conference on Lung Cancer in Barcelona. Patients lived a median 13 months on the Imfinzi combo, versus 10.3 months on chemo. At the 18-month mark, 33.9% of Imfinzi patients were still alive, compared with 24.7% of those who received solo chemo.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001102 seconds